A. Reid

发表

Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa

P. Kaleebu, D. Pillay, C. Gale, 2006, AIDS.

Factors influencing treatment failure in HIV positive adult patients on first line antiretroviral therapy.

A. Reid, C. Nhachi, T. Bwakura, 2014, The Central African journal of medicine.

Shifting human resources for health in the context of ART provision: qualitative and quantitative findings from the Lablite baseline study

J. Seeley, P. Revill, H. Namata, 2016, BMC Health Services Research.

Glomerular Dysfunction and Associated Risk Factors over 4–5 Years following Antiretroviral Therapy Initiation in Africa

A. Walker, C. Gilks, D. Gibb, 2011, Antiviral therapy.

Superior virological suppression with nevirapine/zidovudine/lamivudine versus abacavir/zidovudine/lamivudine without evidence of clinical benefit to 48 weeks: a randomised comparison in patients with low CD4 counts in Africa.

P. Kaleebu, C. Gilks, D. Gibb, 2007 .

Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48‐week randomized comparison with abacavir/zidovudine/lamivudine in HIV‐infected Ugandan adults with low CD4 cell counts

C. Gilks, J. Darbyshire, D. Gibb, 2010, HIV medicine.

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

P. Easterbrook, H. Namata, A. Siika, 2018, The Lancet. Infectious diseases.

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

K. C. Morris, Mohammed Salah Ibrahim, K. Y. Wong, 2022, medRxiv.

Dynamic logistic regression model and population attributable fraction to investigate the association between adherence, missed visits and mortality: a study of HIV-infected adults surviving the first year of ART

Pauliina Ilmonen, H. Oja, A. Walker, 2013, BMC Infectious Diseases.

Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa

Michael I. Jordan, Donald A. Jackson, J. G. Ndirangu, 2016, Journal of the International AIDS Society.

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial

P. Easterbrook, T. Peto, N. French, 2017, The lancet. HIV.

Prevalence, Incidence and Predictors of Severe Anaemia with Zidovudine-Containing Regimens in African Adults with HIV Infection within the Dart Trial

A. Walker, C. Gilks, J. Darbyshire, 2005, Antiviral therapy.

Patterns of Individual and Population-Level Adherence to Antiretroviral Therapy and Risk Factors for Poor Adherence in the First Year of the DART Trial in Uganda and Zimbabwe

Jim Todd, Francis Ssali, Paula Munderi, 2008, Journal of acquired immune deficiency syndromes.

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Steve B Jones, K. Y. Wong, Chamil H. Hettiarachchi, 2021, Lancet.

Impact of acute, oral ingestion of hypoxoside from African potato on hepatic and renal function tests in HIV infected patients on combination antiretroviral therapy.

M. Gundidza, G. Morse, C. Nhachi, 2021, Journal of Herbal Medicine.

Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.

Matthew A. Wiles, Nerissa C. Brown, Christopher M. Horvat, 2022, JAMA.

Incidence of testicular germ‐cell malignancies in England and Wales: Trends in children compared with adults

A. Swerdlow, C. Stiller, A. Reid, 1999, International Journal of Cancer.

Lablite: baseline mapping survey of decentralised ART service provision in Malawi, Uganda and Zimbabwe.

J. Seeley, P. Revill, H. Namata, 2012 .

Pregnancy rates and outcomes among women on triple-drug antiretroviral therapy (ART) in the DART trial.

C. Gilks, D. Gibb, C. Kityo, 2009 .

Pharmacokinetics of Lopinavir-Ritonavir with and without Nonnucleoside Reverse Transcriptase Inhibitors in Ugandan HIV-Infected Adults

C. Gilks, D. Gibb, F. Ssali, 2010, Antimicrobial Agents and Chemotherapy.

Supporting Information S1

Charles F. Gilks, Heiner Grosskurth, Peter Mugyenyi, 2010 .

The Lablite project: A cross-sectional mapping survey of decentralized HIV service provision in Malawi, Uganda and Zimbabwe

J. Seeley, P. Revill, H. Namata, 2014, BMC Health Services Research.

Most HIV-infected individuals on antiretroviral therapy ( ART ) in low and middle-income countries are treated following the World Health

J. Seeley, P. Revill, H. Namata, 2014 .

Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.

A. Breckenridge, P. Kaleebu, D. Pillay, 2010, Lancet.

High Rate of HIV Resuppression After Viral Failure on First-line Antiretroviral Therapy in the Absence of Switch to Second-line Therapy

A. Breckenridge, P. Kaleebu, D. Pillay, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial

J. Seeley, A. Shali, A. Walker, 2018, The lancet. HIV.

Assessment of second-line antiretroviral regimens for HIV therapy in Africa.

P. Easterbrook, A. Siika, A. Kambugu, 2014, The New England journal of medicine.

A Single CD4 Test with 250 Cells/Mm3 Threshold Predicts Viral Suppression in HIV-Infected Adults Failing First-Line Therapy by Clinical Criteria

C. Gilks, E. Katabira, A. Walker, 2013, PloS one.

Lopinavir/Ritonavir Monotherapy after 24 Weeks of Second-Line Antiretroviral Therapy in Africa: A Randomized Controlled Trial (Sara)

P. Kaleebu, D. Pillay, C. Gilks, 2012, Antiviral therapy.

Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial

J. Seeley, K. Maitland, A. Shali, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy.

I. Williams, C. Gilks, D. Gibb, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort

C. Gilks, J. Darbyshire, E. Katabira, 2010, The Lancet.

Glomerular Dysfunction and associated Risk Factors following Initiation of ART in Adults with HIV Infection in Africa: a subanalysis in the DART Trial.

C. Gilks, F. Ssali, W. Stöhr, 2006 .

Implementation of antiretroviral therapy for life in pregnant/breastfeeding HIV+ women (Option B+) alongside rollout and changing guidelines for ART initiation in rural Zimbabwe: the Lablite Project experience

J. Seeley, C. Gilks, E. Katabira, 2017, Journal of acquired immune deficiency syndromes.

Nursing and community rates of Mycobacterium tuberculosis infection among students in Harare, Zimbabwe.

Y. Cheung, S. Munyati, E. Corbett, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial

P. Easterbrook, N. French, H. Namata, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy

A. Walker, S. Khoo, D. Gibb, 2007, AIDS.

Impact of second-line antiretroviral regimens on lipid profiles in an African setting: the DART trial sub-study

W. Tinago, C. Gilks, E. Katabira, 2014, AIDS Research and Therapy.

Cost Effectiveness Analysis of Clinically Driven versus Routine Laboratory Monitoring of Antiretroviral Therapy in Uganda and Zimbabwe

C. Gilks, J. Darbyshire, J. Kigozi, 2012, PloS one.

Immunological response to boosted PI-containing second line ART after switching for clinical/immunological criteria is comparable to response to first-line in patients with low CD4 counts in Africa.

C. Gilks, J. Darbyshire, C. Chimbetete, 2008 .

Impact of routine laboratory monitoring over 5 years after antiretroviral therapy (ART)initiation on clinical disease progression of HIV-infected African adults: the DART Trial finalresults

C. Gilks, J. Darbyshire, E. Katabira, 2009 .

Does Cotrimoxazole Prophylaxis Improve Outcomes after ART Initiation in HIV-infected African Adults? A Causal Analysis Using Marginal Structural Models.

C. Gilks, A. Kambugu, F. Ssali, 2008 .

Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda

D. Pillay, J. Kigozi, E. Katabira, 2014, The Journal of antimicrobial chemotherapy.

Cost Effectiveness Analysis of Routine Laboratory or Clinically Driven Strategies for Monitoring Anti-Retroviral Therapy in Uganda and Zimbabwe (DART Trial)

C. Gilks, J. Darbyshire, J. Kigozi, 2009 .

48 week virological response to a triple nucleoside/nucleotide analogue regimen in adults with HIV infection in Africa within the DART trial.

P. Kaleebu, P. Mugyenyi, D. Yirrell, 2005 .

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

K. C. Morris, Michele R. Shaw, Mohammed Salah Ibrahim, 2023, The Lancet.

C. Gilks, J. Darbyshire, D. Gibb, 2010, HIV medicine.

Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial

A. Breckenridge, P. Kaleebu, D. Pillay, 2010, The Lancet.

Assessment of second-line antiretroviral regimens for HIV therapy in Africa.

P. Easterbrook, A. Siika, A. Kambugu, 2014, The New England journal of medicine.